Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review

World Journal of Gastroenterology

Volumn 20, Issue 20, 2014, Pages 6081-6091

  Fornaro, Lorenzo ^a   Caparello, Chiara ^b   Vivaldi, Caterina ^b   Rotella, Virginia ^a   Musettini, Gianna ^b   Falcone, Alfredo ^b   Baldini, Editta ^a   Masi, Gianluca ^b  

^a Division of Medical Oncology Azienda USL2 Lucca   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Bevacizumab; Chemotherapy; Locally advanced rectal cancer; Neoadjuvant treatment; Radiotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; INDUCTION CHEMOTHERAPY; META ANALYSIS (TOPIC); MICROMETASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; SYSTEMATIC REVIEW; ADENOCARCINOMA; ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; ONCOLOGY; PREOPERATIVE PERIOD; PROGNOSIS; RADIOTHERAPY; RECTAL NEOPLASMS; TREATMENT OUTCOME; TRENDS;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PREOPERATIVE PERIOD; PROGNOSIS; RADIOTHERAPY; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84901478805     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i20.6081     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
2. Berardi R, Maccaroni E, Onofri A, Giampieri R, Bittoni A, Pistelli M, Scartozzi M, Pierantoni C, Bianconi M, Cascinu S. Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. Expert Opin Pharmacother 2009; 10: 2245-2258 [PMID: 19640208 DOI: 10.1517/14656560 903143776]
3. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28: 1638-1644 [PMID: 20194850 DOI: 10.1200/JCO.2009.25.8376]
4. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or with-out oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780 [PMID: 21606427 DOI: 10.1200/ JCO.2010.34.4911]
5. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13: 679-687 [PMID: 22627104 DOI: 10.1016/S1470-2045(12)70187-0]
6. Fornaro L, Masi G, Loupakis F, Vasile E, Falcone A. Palliative treatment of unresectable metastatic colorectal cancer. Expert Opin Pharmacother 2010; 11: 63-77 [PMID: 20001430 DOI: 10.1517/14656560903427997]
7. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049 [PMID: 18463380 DOI: 10.1056/NEJMra0706596]
8. Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y, Jain RK. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 2006; 33: S35-S40 [PMID: 17145523]
9. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147 [PMID: 14745444]
10. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23: 8136-8139 [PMID: 16258121]
11. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026 [PMID: 19470921 DOI: 10.1200/JCO.2008.21.1771]
12. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, Wolff RA, Krishnan S, Hamilton S, Janjan NA, Maru DM, Ellis LM, Rodriguez-Bigas MA. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76: 824-830 [PMID: 19464823 DOI: 10.1016/j.ijrobp.2009.02.037]
13. Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, Edhemovic I, Brecelj E, Kropivnik M, Omejc M. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol 2011; 6: 105 [PMID: 21880132 DOI: 10.1186/1748-717X-6-105]
14. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23 [PMID: 9112145]
15. Villacampa MM, Capdevila J, Manzano JL, Pericay C, Salazar R, López-López C, Losa F, Safont MJ, Gomez A, Alonso V, Escudero MP, Plazas JG, Sastre J, Gravalos Castro C, Biondo S, Palacios A, Aranda E. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer. J Clin Oncol 2012; 30 Suppl: Abstr 3571
16. Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, Nagayama S, Morosini P, Toi M. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis 2012; 15: 141-150 [PMID: 22212406 DOI: 10.1007/s10456-011-9250-0]
17. Marijnen CA, Rutten H, de Wilt H, Tesselaar ME, Nuyttens J, Remmelzwaal J, Punt CJ, Martijn H, Hospers GA, Cats A. Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: a feasibility study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008; 26 (20 suppl): Abstr 15040
18. Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys 2007; 68: 472-478 [PMID: 17498568]
19. Dellas K, Höhler T, Reese T, Würschmidt F, Engel E, Rödel C, Wagner W, Richter M, Arnold D, Dunst J. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol 2013; 8: 90 [PMID: 23587311]
20. Kennecke H, Berry S, Wong R, Zhou C, Tankel K, Easaw J, Rao S, Post J, Hay J. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer 2012; 48: 37-45 [PMID: 21664123 DOI: 10.1016/ j.ejca.2011.05.016]
21. Landry JC, Feng Y, Cohen SJ, Staley CA, Whittington R, Sigurdson ER, Nimeiri H, Verma U, Prabhu RS, Benson AB. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer 2013; 119: 1521-1527 [PMID: 23288663 DOI: 10.1002/cncr.27890]
22. Beg MS, Meyer J, Balch GC, Xie XJ, Singal AG. Pathological complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role? J Clin Oncol 2012; 30 Suppl 4: Abstr 597
23. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010; 21: 1743-1750 [PMID: 20231300 DOI: 10.1093/annonc/mdq054]
24. Fernández-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28: 859-865 [PMID: 20065174 DOI: 10.1200/JCO.2009.25.8541]
25. Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRIdefined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 241-248 [PMID: 20106720 DOI: 10.1016/S1470-2045(09)70381-X]
26. Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, Sikov W, McNulty B, Shipley J, Anderson E, Khurshid H, Oconnor B, Oldenburg NB, Radie-Keane K, Husain S, Safran H. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82: 124-129 [PMID: 20947267 DOI: 10.1016/j.ijrobp.2010.08.005]
27. Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I, Ruiz A, Pericay C. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011; 16: 614-620 [PMID: 21467148 DOI: 10.1634/theoncologist.2010-0285]
28. Vivaldi C, Morvillo M, Masi G, Schirripa M, Sainato A, Montrone S, Loupakis F, Musettini G, Lonardi S, Bergamo F, Friso ML, Menghini V, Mazzotta V, Lucchesi S, Marcucci L, Franceschi M, Marioni A, Sidoti F, Buccianti P, Falcone A. Preliminary safety analysis of a phase II trial with FOLFOXIRI and bevacizumab (BV) followed by chemo-radiotherapy (CRT) in locally advanced rectal cancer (LARC) (TRUST trial). Tumori 2013; 14 Suppl: Abstr A18
29. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010; 11: 845-852 [PMID: 20702138 DOI: 10.1016/ S1470-2045(10)70175-3]
30. Falcone A, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Trenta P, Tomasello G, Ronzoni M, Ciuffreda L, Zaniboni A, Tonini G, Buonadonna A, Valsuani C, Chiara S, Carlomagno C, Boni C, Marcucci L, Boni L, Loupakis F. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. J Clin Oncol 2013; 31 Suppl: Abstr 3505
31. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014; 32: 513-518 [PMID: 24419115]
32. Hasegawa J, Mizushima T, Kim HM, Miyake Y, Takemoto H, Tamagawa H, Noura S, Ohue M, Fujii M, Fujie Y, Ota H, Kato T, Fukunaga M, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M. Neoadjuvant capecitabine and oxaliplatin (XELOX) with bevacizumab for locally advanced rectal cancer. J Clin Oncol 2013; 30 Suppl 34: Abstr 566
33. Fernandez-Martos C, Estevan R, Salud A, Pericay C, Gallen M, Sierra E, Serra J, Pera M, Maurel J, Delgado S, Safont MJ, Roig JV, Aparicio J, Feliu J, Garcia D, Vera R, Suarez J, Alonso V, Martin-Richard M, Brown G. Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. J Clin Oncol 2012; 30 Suppl: Abstr 3586
34. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835 [PMID: 18398148 DOI: 10.1200/JCO.2007.13.7679]
35. Petrelli F, Sgroi G, Sarti E, Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-Analysis of Published Studies. Ann Surg 2013; Epub ahead of print [PMID: 24263329]
36. Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 3: CD004078 [PMID: 22419291 DOI: 10.1002/14651858. CD004078.pub2]
37. Bosset JF, Calais G, Mineur L, Maingon P, StojanovicRundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15: 184-190 [PMID: 24440473 DOI: 10.1016/S1470-2045(13)70599-0]
38. Breugom AJ, van der Broek CBM, van Gijn W, Putter H, Meershoek E, Kranenbarg K, Glimelius B, Pahlman L, Rutten HJT, Marijenn CAM, van der Velde CJH. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemoradiation followed by TME-surgery: The PROCTOR/SCRIPT study. Eur J Cancer 2013; 49 Suppl 3: S1
39. Costa-Silva L, Brown G. Magnetic resonance imaging of rectal cancer. Magn Reson Imaging Clin N Am 2013; 21: 385-408 [PMID: 23642559 DOI: 10.1016/j.mric.2013.01.006]
40. Chua YJ. Pathological complete response: still a relevant endpoint in rectal cancer? Lancet Oncol 2010; 11: 807-808 [PMID: 20692871 DOI: 10.1016/S1470-2045(10)70189-3]